

present with early and progressive changes in language function, and two syndromes have been recognized: semantic dementia (SD) and primary progressive non-fluent aphasia (PNFA) [40, 43, 53, 65, 67, 78]. In later stages of these particular syndromes, both behavioral and language dysfunction may be present. A proportion of patients with FTLD present with or develop parkinsonism as part of their disease process. Clinical amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) may also be found in a proportion of patients with FTLD, especially those with FTD, indicating a spectrum of clinical phenotypes that relate to common neuropathologic lesions [3, 61, 69].

FTD, SD, or PNFA refer to the main clinical syndromes linked to the FTLD group. Typically, at least in the early course of the disease, patients with FTD do not have an amnesic syndrome, which distinguishes them clinically from AD [46, 53], but there are exceptions [29]. Although no pre-symptomatic biomarkers have been identified, at least in sporadic cases, clinical assessment, neuropsychology, and neuroimaging may help to distinguish FTD and the related disorders of SD and PNFA from other neurodegenerative causes of dementia [12, 43, 46]. The diagnosis of FTD, SD, or PNFA may only be considered when other potential causes of dementia including other nervous system diseases (e.g., small and large vessel disease), systemic conditions (e.g., hypothyroidism), tumors, and substance abuse have been excluded.

The *apolipoprotein E (APOE)* gene $\epsilon 4$ allele is a major risk factor for AD, though this is not the case in most association studies of FTLD (but see ref. [71]), and none of the autosomal dominant mutations in genes associated with some familial cases of AD [*amyloid precursor protein (APP)*, *presenilin 1 (PS1)* and *presenilin 2 (PS2)*] acts as a risk factor for FTLD.

Recent developments in the molecular pathology and genetics of FTLD now dictate that a minimal panel of pathological investigations is required for correct diagnosis in this group of diseases. Standardization of nomenclature and approach will facilitate better understanding of clinico-pathologic correlations, provide insights into pathogenesis, and guide the construction and validation of *in vivo* models.

Neuropathologic evaluation

With the exception of those cases in which a gene defect has been identified, examination of the brain and neuropathology are essential in order to determine the disease entity underlying FTLD. Even in those cases that have been genetically characterized, it is not uncommon to find coexisting neurodegenerative disease and other pathology, which may have contributed to the clinical picture to a varying degree. The neuropathology of the brain, either on autopsy or, rarely, on

biopsy, remains the “gold standard” for determining the neuropathologic diagnosis. Although most cases seen by a neuropathologist are likely to be cases of advanced disease, there is an increasing awareness that the molecular pathology of all neurodegenerative disease is present often several years prior to the onset of clinical symptoms, and this knowledge will inform the neuropathologist of pre-clinical FTLD in an otherwise cognitively and behaviorally normal subject.

Macroscopy

Examination of the brain of a patient with FTLD typically shows symmetrical focal atrophy of the frontal or temporal lobes, or both. In some patients there is asymmetry of atrophy, typically reflected in perisylvian loss on one side of the brain. Macroscopic atrophy of the basal ganglia and loss of pigmentation from the substantia nigra are seen in a proportion of cases. This focal atrophy is, not infrequently, the most dramatic in all of neuropathology. Conversely, in some individuals, for example, those who die at an earlier stage, the brain is unremarkable. The pattern of atrophy may assist in staging disease severity [11, 39, 41].

Microscopy

In most forms of FTLD, examination of the cerebral cortex with H&E staining shows microvacuolation and neuronal loss. In many cases, this is most evident around layer II of the affected cortical regions. In advanced cases, there is transcortical microvacuolation and neuronal loss. Swollen cortical neurons may be seen and highlighted with immunostaining for alpha B-crystallin; however, they are not specific for any disease subtype. White matter myelin loss and astrocytic gliosis may be seen. There may be significant neuronal loss from the basal ganglia and substantia nigra in some cases.

Specific diagnosis of disease within the broad group of FTLD now requires immunohistochemistry (IHC) to determine the molecular pathology, morphology, and distribution of lesions in the neuraxis, and thereby identify the neurodegenerative disease. In the routine microscopic evaluation of the brain of a patient with FTLD, other neurodegenerative diseases may be identified, most commonly AD [18], DLB [52], and, rarely, prion disease [33] and hereditary diffuse leukoencephalopathy with axonal spheroids [76].

Although some neurodegenerative diseases can be readily identified using conventional staining techniques (e.g., modified Bielschowsky and Gallyas silver impregnations and thioflavine-S for AD pathology [8, 18, 54]), more sensitive and reliable IHC techniques are now preferred. IHC methods are more consistent and dependable than are silver impregnation techniques, they have greater inter-rater reliability, as shown by the BrainNet Europe Consortium study [1], and IHC results can suggest or identify underlying molecular pathology.

For example, antibodies raised against epitopes of tau readily label the neurofibrillary tangles, neuritic plaques, and neuropil threads of AD; anti- β -amyloid antibodies detect diffuse and compact β -amyloid deposits and cerebral amyloid angiopathy [10]; while anti- α -synuclein antibodies label Lewy bodies and Lewy neurites, the signature lesions of DLB [10, 52]. Neuropathologic staging schemes have been developed using tau, β -amyloid and α -synuclein IHC, and IHC is now replacing conventional stains in the neuropathologic diagnostic criteria for AD and DLB [10, 18, 52]. Prion IHC may be used reliably to detect or exclude prion disease in most cases [33]. Proteins targeted for degradation are ubiquitinated and several hallmark inclusions in neurodegenerative disease either in neurons or glia or both are detected by ubiquitin IHC [17, 19, 47, 48]. There is also age-related accumulation of ubiquitinated material in the brain [23], which can make detection of certain ubiquitin-related pathologies difficult. Until recently, ubiquitin IHC was the only marker for certain neuronal inclusions seen in FTLD and ALS/MND that contained neither tau nor α -synuclein epitopes. P62 (sequestosome-1) IHC has recently been highlighted as an alternative method to detect a range of ubiquitin-immunoreactive structures in neurodegenerative diseases including ALS/MND, and FTLD. Like ubiquitin IHC, a range of pathological and age-related abnormalities are detected, but an advantage over anti-ubiquitin IHC appears to be that there is better contrast in the detection of intracellular pathology. More recently, TDP-43 has been identified as a major component of the inclusions of FTLD with ubiquitin-positive, tau- and α -synuclein-negative inclusions (FTLD-U) [3, 61], formerly called FTLD with MND-type inclusions, but without MND [53]. This protein now defines a novel class of neurodegenerative diseases collectively called TDP-43 proteinopathies [16], and TDP-43 IHC may be used to characterize a majority of FTLD-U, but not all [16].

Although IHC is essential for determining the underlying molecular pathology of the majority of neurodegenerative diseases, other techniques may be available in dementia research centers and complement the routine neuropathologic diagnosis. The reliable and robust detection of abnormally aggregated proteins either within neurons or glia or both, or in the neuropil, is necessary for neuropathologic diagnosis. However, the density and distribution of abnormal protein aggregates, as identified by IHC, do not always correlate well with clinical symptoms. Other markers, such as synaptic and neuronal loss in affected brain areas, may correlate better with cognitive impairment and motor dysfunction. Thus, stereologic methods that assess synaptic and neuronal loss in an unbiased manner may be useful in clinico-pathologic studies in the dementia research center, but are not necessary, or usually feasible, for routine neuropathologic diagnosis.

Biochemistry is also useful, but not essential for diagnosis. Methods of fractionating brain homogenates may be used

to rationally classify the tauopathies in a research setting [13]. In the adult brain, there are normally six isoforms of the microtubule-associated protein tau (MAPT): three isoforms with 0, 1, or 2 inserts contain three microtubule-binding repeats (3R tau) and three isoforms, also with 0, 1, or 2 inserts, contain four microtubule-binding repeats (4R tau) [28]. The tauopathies have a biochemical signature: tau protein in these disorders is relatively insoluble and these insoluble species can be detected by biochemical fractionation methods. The insoluble fractions may be further characterized according to the pattern of tau isoforms. For example, in AD, all six isoforms are abnormally hyperphosphorylated and migrate as three major bands and one minor band when visualized by immunoblotting. Treatment with the enzyme alkaline phosphatase removes phosphate groups, and the tau isoforms appear as six bands (3R and 4R tau). This biochemical signature may be used to distinguish AD from the FTLD tauopathies [13]. Thus, brain tissue from patients with FTLD where Pick bodies are present is characterized biochemically by predominantly 3R tau, while CBD, PSP, argyrophilic grain disease (AGD), and sporadic multiple system tauopathy with dementia (MSTD) are predominantly 4R tauopathies [13, 74], and neurofibrillary tangle dementia (NTD), also called tangle predominant form of senile dementia, has inclusions containing a mixture of 3R and 4R tau [34, 35]. FTLD with *MAPT* mutation, of which more than 40 have been described, is biochemically heterogeneous with different mutations being associated with 3R, 4R, or 3R and 4R tauopathy [15]. Monoclonal antibodies, which discriminate between 3R and 4R tau [22] are now commercially available; so, the molecular classification of tauopathies by isoform type may be easily undertaken in the histology laboratory that does not have access to biochemistry.

FTLD with ubiquitin-positive, tau-negative inclusions (FTLD-U), also known as FTLD with MND-type inclusions or MND inclusion dementia, is the most common underlying pathology in FTLD with and without clinical MND [45, 73]. TAR DNA-binding protein 43 (TDP-43), a nuclear protein implicated in exon skipping and transcription regulation, was recently identified as a major protein component of the ubiquitin-immunoreactive inclusions characteristic of sporadic and familial FTLD-U, with and without clinical MND, as well as in sporadic ALS [3, 16, 21, 61]. Biochemistry in these disorders shows TDP-43 to be abnormally phosphorylated, ubiquitinated and cleaved to generate C-terminal fragments, and is recovered only from areas with ubiquitin-immunoreactive inclusions including hippocampus, neocortex, and spinal cord [61]. The neuropathology of these conditions is characterized by ubiquitin- and TDP-43-positive neuronal cytoplasmic inclusions (NCIs), neuronal intranuclear inclusions (NIIs), dystrophic neurites (DNs), and glial cytoplasmic inclusions (GCIs) that are negative for tau, α -synuclein, β -amyloid, neuronal

intermediate filaments, and expanded polyglutamines [21, 61]. The variability in the morphologic types of neuronal inclusions, their distribution, density, and immunohistochemical profile has led to the proposed classification of FTLD-U into four pathologic subtypes [16, 63, 66]. Recently, mutations in the *progranulin* (*PGRN*) gene [4, 20, 57], the molecular genetic basis of non-tau familial FTD linked to chromosome 17, were discovered. The neuropathology in these cases is FTLD-U with ubiquitin-positive neurites, NCIs and, most characteristically, NIIs [4, 50] (but see ref. [37]). However, NIIs can be seen in other FTLD-U cases where *PGRN* mutations are not found [16] and therefore such NIIs cannot be considered pathognomonic for *PGRN* or other (i.e., *valosin-containing protein* *VCP*) mutations associated with FTLD. As demonstrated by IHC and biochemistry, the ubiquitinated pathologic protein in these cases is not progranulin, but TDP-43 [4, 57]. Pathologic TDP-43 is detected biochemically in both affected gray and white matter, suggesting that both glial and neuronal pathology may contribute to the pathogenesis of FTLD-U caused by *PGRN* mutations [61].

Frontotemporal lobar degeneration with *VCP* gene mutation, also called inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD), is a rare autosomal dominant disorder caused by mutations in the *VCP* gene [77]. *VCP*, a member of the AAA-ATPase gene super family (ATPase associated with diverse cellular activities), has multiple cellular functions including acting as a molecular chaperone in endoplasmic reticulum-associated protein degradation, stress response, programmed cell death, and interactions with the ubiquitin-proteasome system. The neuropathology in FTLD with *VCP* mutation is a unique subtype of FTLD-U and is characterized by numerous NIIs and relatively few NCIs and DNIs [26]; the ubiquitinated inclusions are not primarily composed of the mutated protein (*VCP*), but rather TDP-43 [26, 63].

Frontotemporal lobar degeneration with *charged multivesicular body protein 2B* (*CHMP2B*) gene mutation is the cause of FTD linked to chromosome 3 in a large Danish pedigree [68]. Human *CHMP2B* is a component of the endosomal secretory complex, which becomes dysregulated by the gene defects. Recent studies have revealed ubiquitin-positive, but TDP-43 negative, NCIs in the frontal neocortex and hippocampus, so that this disease is an FTLD-U, but not a TDP-43, proteinopathy [16].

A genetic locus on chromosome 9p for familial FTD-MND has been described [56]. In one family, candidate gene sequencing revealed the presence of a putative disease segregating stop codon mutation (Q342X) in the *intraflagellar transport protein 74* (*IFT74*) gene [55]. *IFT74* is a protein that localizes to the intracellular vesicle compartment and is a component of the intraflagellar transport system responsible for vesicular transport of material synthesized

within the cell body into and along dendrites and axons. Neuropathology in a single case with the *IFT74* mutation was reported as showing all the stigmata of FTLD-U (ubiquitinated NCIs, DNIs, and NIIs) and TDP-43 proteinopathy similar to that seen in other reported families with FTD, with or without MND linked to chromosome 9p [16]. Nonetheless, it remains to be established in other families and patients that *IFT74* is indeed a true locus for FTLD.

Neuropathologic classification of FTLDs

Following the principles of the previous consensus criteria for the neuropathologic diagnosis of FTLD [53], and the consensus criteria for the postmortem diagnosis of AD [18] and DLB [52], we acknowledge that only probabilistic statements can be made as to the causal relationship between the neuropathology and the clinical phenotype. Just as the constellation of clinical symptoms associated with FTD, SD, or PNFA do not predict reliably the underlying causative neurodegenerative disease, the presence of the neuropathology of FTLD does not predict with certainty one or other of the clinical phenotypes associated with FTLD, or even if the subject was demented. Small series of cases are inadequate to reliably and robustly determine clinico-pathologic correlations with any one form of FTLD. Multi-center collaborations are beginning to address this challenge [25], and it is only by pooling relatively rare cases from several research centers that reliable clinico-pathologic correlations are likely to emerge.

The neuropathologic criteria proposed here (Table 1) are an evolution of the 2001 criteria proposed by McKhann et al. [53], and take into account more recent descriptions of novel disease entities [6, 14], the discovery of causative gene defects (*PGRN*, *VCP*, *CHMP2B*) and linkage to chromosome 9p [4, 5, 20, 55, 56, 57, 68, 75, 77], and the novel (TDP-43) proteinopathy, which is present in most cases of FTLD-U with or without MND [3, 16, 21, 61]. The neuropathologic diagnosis of FTLD requires the exclusion of other neurodegenerative and systemic diseases, tumors, and drugs of abuse, which may cause a clinical FTLD phenotype. The proposed rational classification of neurodegenerative diseases associated with a clinical FTLD phenotype comprises seven distinct neurohistological types, and is based on the underlying molecular pathology as far as it is known.

Algorithm for the neuropathologic diagnosis of FTLD

The proposed criteria for the neuropathologic diagnosis and nosology of FTLD builds on, and extends, the existing criteria to include neuropathologic assessment using disease-specific antibodies, biochemistry, and molecular genetics to

Table 1 Comparison between the present proposed criteria and McKhann et al. [3] neuropathologic diagnostic criteria for FTLD

Present criteria	McKhann et al. criteria
1. Tauopathy (with associated neuron loss and gliosis) and insoluble tau with a predominance of 3R tau, the most likely diagnoses are: FTLD with Pick bodies FTLD with <i>MAPT</i> mutation	1. When the predominant neuropathological abnormalities are tau-positive inclusions (with associated neuron loss and gliosis) and insoluble tau has a predominance of tau with three microtubule-binding repeats, the most likely diagnoses are: (a) Pick disease (b) Frontotemporal dementia with parkinsonism linked to chromosome 17 (c) Other as yet unidentified familial and sporadic frontotemporal disorders
2. Tauopathy (with associated neuron loss and gliosis) and insoluble tau with a predominance of 4R tau, the most likely diagnoses are: Corticobasal degeneration Progressive supranuclear palsy Argyrophilic grain disease Sporadic multiple system tauopathy with dementia FTLD with <i>MAPT</i> mutation	2. When the predominant neuropathological abnormalities are tau-positive inclusions (with associated neuron loss and gliosis) and insoluble tau has a predominance of four microtubule-binding repeats, the most likely diagnoses are: (a) Corticobasal degeneration (b) Progressive supranuclear palsy (c) Frontotemporal dementia with parkinsonism linked to chromosome 17 (d) Other as yet unidentified familial and sporadic frontotemporal disorders
3. Tauopathy (with associated neuron loss and gliosis) and insoluble tau, with a predominance of 3R and 4R tau, the most likely diagnoses are: Neurofibrillary tangle dementia FTLD with <i>MAPT</i> mutation	3. When the predominant neuropathological abnormalities are tau-positive inclusions (with associated neuron loss and gliosis) and insoluble tau has a predominance of three and four microtubule-binding repeats, the most likely diagnoses are: (a) Neurofibrillary tangle dementia (b) Frontotemporal dementia with parkinsonism linked to chromosome 17 (c) Other as yet unidentified familial and sporadic frontotemporal disorders
4. Frontotemporal neuronal loss and gliosis without tau- or ubiquitin/P62-positive inclusions, the most likely diagnosis is: FTLD (also known as dementia lacking distinctive histologic features)	4. When the predominant neuropathological abnormalities are frontotemporal neuronal loss and gliosis without tau- or ubiquitin-positive inclusions and without detectable amounts of insoluble tau, the most likely diagnoses are: (a) Frontotemporal lobar degeneration (also known as dementia lacking distinct histopathological features) (b) Other as yet unidentified familial and sporadic frontotemporal disorders
5. TDP-43 proteinopathy with associated neuronal loss and ubiquitin-positive/P62-positive, tau-negative inclusions, with MND or without MND but with MND-type inclusions, the most likely diagnoses are: FTLD-U with MND (FTLD-U types 1–3) FTLD-U but without MND (FTLD-U types 1–3) FTLD-U with <i>PGRN</i> mutation (FTLD-U type 3) FTLD-U with <i>VCP</i> mutation (FTLD-U type 4) FTLD-U linked to chromosome 9p (FTLD-U type 2) Other as yet unidentified TDP-43 proteinopathies	5. When the predominant neuropathological abnormalities are frontotemporal neuronal loss and gliosis with ubiquitin-positive, tau-negative inclusions and without detectable amounts of insoluble tau, with MND or without MND but with MND-type inclusions, the most likely diagnoses are: (a) Frontotemporal lobar degeneration with MND (b) Frontotemporal lobar degeneration with MND-type inclusions but without MND, or (c) Other as yet unidentified familial and sporadic frontotemporal disorders.

Table 1 continued

Present criteria McKhann et al. criteria

6. Frontotemporal neuronal loss and gliosis with ubiquitin-positive/P62-positive, TDP-43- and tau-negative inclusions, the most likely diagnoses are:

FTLD-U with *CHMP2B* mutation

Basophilic inclusion body disease (BIBD)

Other as yet unidentified FTLD-U, non-TDP-43 proteinopathies

7. Frontotemporal neuronal loss and gliosis with ubiquitin/P62 and α -internexin-positive inclusions, the most likely diagnosis is:

Neuronal intermediate filament inclusion disease (NIFID)

CHMP2B charged multivesicular body protein 2B gene, *FTLD* frontotemporal lobar degeneration, *FTLD-U* FTLD with ubiquitin-positive, tau-, α -synuclein-, TDP-43-, and neuronal intermediate filament protein-negative inclusions, *MAPT* microtubule-associated protein tau gene, *MND* motor neuron disease, neurofibrillary tangle dementia, also called tangle predominant form of senile dementia, *PGRN* progranulin gene, *TDP-43* TAR DNA-binding protein 43, *VCP* valosin-containing protein gene

FTLD Protocol Flowchart




Fig. 1 Frontotemporal lobar degeneration neuropathology algorithm flow chart. *AD* Alzheimer's disease, *AGD* argyrophilic grain disease, *AMYG* amygdala, *BIBD* basophilic inclusion body disease, *CBD* corticobasal degeneration, *CBLM* cerebellum including the dentate nucleus (*DN*), *CHMP2B* charged multivesicular body protein 2B gene, *CG* cingulate gyrus, *DLB* dementia with Lewy bodies, *DLDH* dementia lacking distinctive histologic features, also called FTLD according to McKhann et al. [4] criteria, *FTLD* frontotemporal lobar degeneration, *FTLD-U* FTLD with ubiquitin-positive, tau-negative inclusions, *GP* globus pallidus, *H&E* hematoxylin and eosin, *HIP* hippocampus, *IHC* immunohistochemistry, *INA* α -internexin, *MAPT* microtubule-associated protein tau gene, *MED* medulla oblongata, *MFG* middle

frontal gyrus, *MID* midbrain including the substantia nigra, *MND* motor neuron disease, *MSTD* sporadic multiple system tauopathy with dementia, *NIFID* neuronal intermediate filament inclusion disease, *NF* neurofilament; neurofibrillary tangle dementia, also called tangle predominant form of senile dementia, *NOS* not otherwise specified, *OL* occipital lobe, *PGRN* progranulin gene, *PL* parietal lobe, *PSP* progressive supranuclear palsy, *SC* spinal cord, *STG* superior temporal gyrus, *STR* striatum, *TDP-43* TAR DNA-binding protein 43, *THAL/SUBTN* thalamus and subthalamic nucleus, *Ub* ubiquitin, *VCP* valosin-containing protein gene, 3R, 4R, or 3R and 4R tau isoforms containing 3, 4, or 3 and 4 microtubule-binding repeats





Fig. 2 Frontotemporal lobar degeneration with Pick bodies. Pick bodies (*arrowheads*) and a neurofibrillary tangle (*arrow*) in the subiculum (**a**) are immunolabeled by anti-phosphorylated tau antibodies (*PHF1* immunohistochemistry). Pick bodies are not immunolabeled

with anti-4R tau antibodies (*arrowheads*), while neurofibrillary tangles are immunolabeled (*arrows*) (**b**). Anti-3R tau antibodies clearly label Pick bodies (*arrowheads*) (**c**). **b** 4R tau (ET3) and **c** 3R tau (RD3) immunohistochemistry. Bars 10 μ m

Fig. 3 Corticobasal degeneration. **a** A swollen achromatic neuron (*arrow*) in the middle frontal gyrus. Hematoxylin and eosin (*HE*). **b** Tau-positive neurofibrillary tangles in the pyramidal neurons of the CA1 hippocampal subfield. **c** A globose neurofibrillary tangle (*arrow*) in the locus coeruleus. **d** An astrocytic plaque (*asterisk*), coiled body (*arrow*), and threads (*arrowhead*) in the deep cortical laminae and white matter of the parietal lobe. **b, c, d** Anti-phosphorylated tau (*PHF1*) immunohistochemistry. Bars 10 μ m




arrive at the neuropathologic diagnosis of one of the disease entities causing FTLD. It is appreciated that it may not be practical, possible, or even necessary, to undertake sophisticated neuroanatomical investigations of neuron and synapse density, biochemistry or molecular genetics in every case. For these reasons, the following neuropathologic algorithm has been developed, which should be feasible at most dementia research centers. It is envisaged that this

algorithm, with its inbuilt criteria for diagnosis, will supersede existing neuropathologic criteria [3], and become the standard operational protocol for the working neuropathologic diagnosis of FTLD (Figs. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14).

Recently, staging schemes have been developed that no longer rely on capricious silver impregnation methods, but employ instead sensitive monoclonal and polyclonal

Fig. 4 Progressivesupranuclear palsy. Neurofibrillary tangles in the subthalamic nucleus (a), oculomotor nucleus (b), and locus coeruleus (e). Tufted astrocytes in the putamen (c and d). a, b, c, e Anti-phosphorylated tau (PHF1) immunohistochemistry. d *Galb* silver impregnation. Scale bars a 50 μ m, b, c, d, e 10 μ m



antibodies that detect, by IHC, the pathologic proteins of the major neurodegenerative diseases [9, 10, 52]. Multi-center studies have confirmed the reproducibility and reliability of IHC over traditional staining methods, and IHC is recommended for the detection of the signature lesions of FTLD [1, 53], when appropriate. Thus, neurodegenerative diseases with α -synuclein pathology, with or without A β plaques and tau-positive neurofibrillary tangle (AD) pathology (i.e., DLB, Parkinson's disease, and multiple system atrophy), or those with plaque and tangle pathology (i.e. Alzheimer disease) are excluded using established sampling schemes and diagnostic criteria for these diseases [18, 52].

Tau-positive inclusions

Where neurofibrillary tangles alone are present, in the absence of A β plaques, in the context of neuronal loss and gliosis, NTD, also called tangle predominant form of senile dementia, which, like AD tangles, contain tau composed of all six isoforms, is a diagnostic possibility. Where the distribution of neuronal and glial tau pathology is more widespread and includes frontal, temporal, and parietal neocortex, basal ganglia, and brainstem nuclei, then sporadic MSTD may be indicated [6]. Neurofibrillary tangles in more subcortical regions including the basal ganglia, subthalamic nucleus, midbrain, and pontine nuclei indicate progressive supranuclear palsy [31, 72]. Distinguishing lesions in PSP are tau-positive tufted astrocytes and are found in affected neocortical and subcortical regions. Corticobasal degeneration is characterized by frontal and temporal atrophy that is not infrequently asymmetric, neuronal

loss, gliosis, swollen achromatic neurons that are faintly tau-positive, and tau-positive neurofibrillary tangles in the neocortex, basal ganglia, and brainstem nuclei [24, 27]. Distinguishing lesions in CBD are tau-positive astrocytic plaques and threads found in the affected neocortex and subcortical white matter and in the basal ganglia. In both PSP and CBD, tau-positive oligodendroglial inclusions called coiled bodies are seen, but these are generally at a lower density than inclusions in astrocytes. Tau-positive ovoid structures (glial processes), astrocytes, and oligodendroglial inclusions (coiled bodies), when confined to the medial temporal lobe and limbic structures, indicate another tauopathy, AGD [7]. If globose tau-positive NCIs, called Pick bodies, are present in the non-pyramidal (dentate gyrus granule cells) and pyramidal neurons of area CA1 of the hippocampus, and pyramidal neurons of the temporal and frontal lobes, then FTLD with Pick bodies may be present [80]. Pick bodies are largely or wholly composed of 3R tau, which can be demonstrated by IHC or immunoblotting, while the tau-positive inclusions of PSP, CBD, MSTD, and AGD all contain 4R tau indicating that these latter disorders may represent a spectrum of 4R tauopathies [13, 74]. Finally, FTLD with *MAPT* mutation, also called FTD with parkinsonism linked to chromosome 17 (FTDP-17), is not only clinically and genetically heterogeneous (more than 40 mutations have been reported in the *MAPT* gene), but is also neuropathologically heterogeneous. The spectrum of neuronal and glial pathology seen in 3R, 4R, and combined 3R and 4R tauopathies is also found in such cases of familial tauopathy [15, 44, 70]. For the practicing neuropathologist, the presence of this spectrum of pathology in a case warrants further genetic investigation particularly if there is an autosomal dominant pattern of




Fig. 5 Argyrophilic grain disease. **A** Swollen achromatic neuron (*arrow*) with pale center and more intense tau-immunoreactive periphery in the subiculum. Tau-immunoreactive grains in the neuropil and diffusely stained pyramidal neurons (*arrow*) indicating a pre-neurofibrillary tangle stage in the pyramidal layer of the hippocampus (**b**). **A** tau-immunoreactive astrocytic inclusion (*arrowhead*) and oligodendroglial cytoplasmic inclusions called coiled bodies (*arrows*) in the CA1 subfield of the hippocampus. (**a, b, c**) Anti-phosphorylated tau (*PHF1*) immunohistochemistry. *Scale bars* (**a**) 100 μm and (**b** and **c**) 50 μm

inheritance. Similar 3R and 4R tau heterogeneity is seen in some tauopathies that cannot be categorized as FTLD with Pick bodies, PSP, CBD, or AGD, and in individuals without *MAPT* mutations. Such a case may have tau pathology in the distribution described in sporadic MSTD, or may have to be categorized as “unclassifiable sporadic tauopathy.”




Fig. 6 Sporadic multiple system tauopathy with dementia. Neuronal and glial globular inclusions at the gray/white junction. Anti-phosphorylated tau (*PHF1*) immunohistochemistry. *Scale bar* 100 μm




Fig. 7 Neurofibrillary tangle dementia. **a, b** Numerous neurofibrillary tangles in the upper and lower pyramidal neurons of the occipitotemporal cortex; no neuritic plaques or amyloid deposits are present. **a** *Gallyas* silver impregnation. **b** Anti-phosphorylated tau (*PHF1*) immunohistochemistry. *Scale bars* 50 μm




Fig. 8 Frontotemporal lobar degeneration (FTLD) with *MAPT* mutation. Inclusions in FTLD with *MAPT* G389R mutation (a) and FTLD with *MAPT* intron 10 + 16 mutation (b–g). **a** Numerous tau-immunoreactive Pick body-like inclusions in the granule neurons of the dentate fascia. **b** A swollen achromatic neuron in the superior temporal gyrus. **c** A swollen neuron with a central area of pale anti-tau immunoreactivity surrounded by more intense staining. Fibrillary material surrounds the nucleus and extends into the apical dendrite. **d** An intraneuronal

inclusion resembling a Pick body in the superior frontal gyrus. **e** A neurofibrillary tangle-like inclusion in layer V of the superior frontal gyrus. **f** A globose neurofibrillary tangle-like inclusion in the dorsal raphe nucleus. **g** An astrocytic fibrillary inclusion (a) and a coiled body (b) in an oligodendrocyte in the white matter of the frontal lobe. **b** Hematoxylin and eosin (HE); (a, c–g) anti-phosphorylated tau (AT8) immunohistochemistry. Scale bars 10 μ m. (Adapted from Ref. [44]; reproduced with permission)

Tau-negative, ubiquitin-positive inclusions

TDP-43 proteinopathy

Immunohistochemistry for ubiquitin, P62, and TDP-43 in cases with FTLD generally reveals similar pathology that includes a spectrum of neuronal (NCIs, DNs, and NIIs) and glial, predominantly oligodendroglial, cytoplasmic inclusions (GCIs) [62, 61]. However, there are significant differences in the immunohistochemical findings with ubiquitin, P62, and TDP-43. Ubiquitin immunoreactivity is present in extensive age-related pathology in gray and white matter, e.g., dot-like bodies and granular degeneration of myelin, which can mask subtle neuronal and glial pathology and can be difficult to interpret. P62 immunostaining detects the same range of pathological structures as anti-ubiquitin, but

highlights less age-related pathology, making interpretation somewhat less demanding. TDP-43 immunoreactivity is present in nuclei of most cell types and changes in distribution within affected neurons in disease. Screening cases using TDP-43 immunostaining as a primary diagnostic tool, as might be used for tau and α -synuclein accumulations, is more demanding. Four histologic subtypes of FTLD-U have been proposed, based on the predominant type of inclusion present as detected using anti-ubiquitin, its distribution in the cortex, and density [16, 63, 66]. Other types have been proposed as well and take into account involvement of other brain regions (e.g., hippocampus or corpus striatum) and the morphology of the lesions [2, 38]. Patterns of FTLD-U histology based solely on cortical pathology include a system proposed by Sampathu et al. [66], and Neumann et al. [63]; while Mackenzie et al. [49]




Fig. 9 Frontotemporal lobar degeneration (FTLD)-U with or without MND: spectrum of *TDP-43* pathology. Adjacent sections of superficial frontal neocortex showing neuronal cytoplasmic inclusions (NCIs), dystrophic neurites (DNs), and isolated neuronal intranuclear inclusions (NIIs) stain for both ubiquitin (a) and *TDP-43* (b). NCI in the dentate granule cells stain for ubiquitin (c) and *TDP-43* (d). Neuronal

and glial inclusions include NCI (e), round and lentiform NIIs (f, g); skein-like (h), and compact round (i) NCI in the lower motor neurons; and glial cytoplasmic inclusion (GCI) (j). (a and c) ubiquitin immunohistochemistry (b, d, e–j *TDP-43* immunohistochemistry). Scale bars 10 μ m (a–d); 5 μ m (e–j) (Adapted from Ref. [16]; reproduced with permission)




Fig. 10 Frontotemporal lobar degeneration-U with MND. Diffuse perinuclear staining in a motor neuron (arrow). *TDP-43* immunohistochemistry. Scale bar 10 μ m

have proposed a system that includes cortical and dentate fascia inclusions. In all these schemes the same descriptors were employed to differentiate subtypes, though the numbering of each subtype differed among schemes. In the present composite scheme, type 1 cases (as in [66], but known as type 2 in Mackenzie et al. [49]) are characterized

by an abundance of long DN, predominantly in the superficial cortical laminae, with few or no NCIs or NIIs. Type 2 cases (as in [66], but known as type 3 in Mackenzie et al. [49]) are characterized by numerous NCIs in both superficial and deep cortical laminae as well as infrequent DN and sparse or no NIIs. Type 3 cases (as in [66], but known as type 1 in Mackenzie et al. [49]) are characterized by pathology predominantly in the superficial cortical layers with numerous NCIs, DN, and variable numbers of NIIs. Type 4 cases [16, 63] are distinguished by numerous NIIs and infrequent NCIs and DN in the neocortical areas with relative sparing of the hippocampus, consistent with the pathology described in cases of FTLD with *VCP* mutations (but see ref. [30]). Consensus on the validity, reliability, and reproducibility of the various proposed typing schemes, as well as their clinical significance, remain to be determined.

If *TDP-43*- and ubiquitin- or P62-positive, tau- and α -synuclein-negative inclusions are found in the superficial laminae of the frontal and temporal neocortex and neurons of the dentate gyrus, the most likely diagnosis is FTLD-U [21, 36, 45]. If in addition, there is *TDP-43* proteinopathy and ubiquitin-positive inclusions in the lower motor neurons and evidence of motor neuron loss, gliosis, Bunina bodies, and corticospinal tract degeneration, FTLD with MND is the most likely diagnosis [53, 64, 79].

Fig. 11 Frontotemporal lobar degeneration-U, subtypes 1–4. **a–d** Type 1 is characterized by long and tortuous dystrophic neurites (DNs) in laminae II/III with relatively few neuronal cytoplasmic inclusions (NCIs) and no neuronal intranuclear inclusion (NII). **b** Type 2 has numerous NCIs, relatively few DN, and no NII is present. **c** Type 3 has numerous NCIs and DN and an occasional NII in lamina II. **d** Type 4 pathology in a case of FTD with *VCP* mutation is characterized by numerous NII and DN, but few NCI. *TDP-43* immunohistochemistry. Scale bar 10 μ m (**a–d**). (Adapted from Ref. [14]; reproduced with permission)



There is heuristic value in the sub-classification of FTLN-U beyond pathologic description alone, with clinical and genetic correlates of histologic patterns emerging. Cases with type 1 histology are associated with SD, whereas cases of FTLN with MND frequently show type 2 histology [49]. In genetic terms, cases with *PGRN* or *VCP* gene mutations, and in cases linked to chromosome 9, distinct patterns of ubiquitin- and TDP-43-positive inclusions are also seen. FTLN with *PGRN* mutation cases often display a PNFA clinical phenotype and exclusively show type 3 histology [16], whereas those with *VCP* mutations have type 4 histology. Cases linked to chromosome 9 have type 2 histology [16] and the majority of such cases also have ubiquitin- and TDP-positive inclusions in the upper and lower motor neurons, identical to those encountered in sporadic MND [16] or sporadic FTLN with MND where a similar type 2 histology is often present [49]. These latter data indicate that the pathology of FTLN linked to chromosome 9p is a specific subtype of FTLN-U (type 2) and that TDP-43 is the disease-associated protein. Biochemistry of sporadic cases of FTLN with and without MND, cases of sporadic ALS, and familial cases of FTLN-U with *PGRN* and *VCP* mutations, and those linked to chromosome 9p, all have a characteristic biochemical signature: TDP-43 is detected in the detergent-insoluble urea fractions from affected regions and is abnormally phosphorylated, with additional protein bands of ~25 and 45 kDa, as well as a high molecular smear, and is ubiquitinated [16, 61, 62, 63]. The quantity of these modified TDP-43 species detected by biochemistry [62, 63] may be variable, but correlates with the amount of pathology detected by IHC. Additionally, the 45 kDa species collapse into a 43 kDa band upon dephosphorylation with alkaline phosphatase, indicating that TDP-43 is abnormally phosphorylated, with features paralleling

the biochemical changes seen in the tauopathies. Hippocampal sclerosis (HS) may be found as a coexisting pathology in FTLN-U with or without MND, and small numbers of ubiquitin- and TDP-43-positive inclusions may be seen exclusively in the dentate granule cells. Preliminary data indicate that some, or perhaps most, cases of HS are TDP-43 proteinopathies [2], but further studies on larger samples of “pure HS” and biochemical studies are required to determine the nosologic status of HS.

TDP-43-negative inclusions

In those cases that have ubiquitin- or P62-positive, TDP-43-, tau-, and α -internexin-negative NCIs in the frontal and temporal lobes and dentate gyrus, the most likely diagnosis is FTLN with *CHMP2B* mutation [16]. Mutations in the *CHMP2B* gene are the cause of FTD-linked to chromosome 3 in a large Danish pedigree [68]. Human *CHMP2B* is a component of the endosomal secretory complex, which becomes dysregulated by the gene defect. However, the absence of DN and the presence of granular, ubiquitin-positive structures within the neocortex of these cases distinguish this FTLN-U subtype from the types 1–4 described above. Thus, based on the small number of cases studied to date, familial FTLN with *CHMP2B* mutation appears to be a distinctive pathologic subtype of FTLN-U and is not a TDP-43 proteinopathy on the basis of IHC.

In cases of FTLN where there is frontotemporal neuron loss and gliosis, α -internexin- or neurofilament-positive, TDP-43-, α -synuclein-, and tau-negative, and variably ubiquitinated but P62-positive neuronal inclusions, the most likely diagnosis is neuronal intermediate filament inclusion disease [14]. Where there is FTLN and P62-positive,




Fig. 12 Frontotemporal lobar degeneration with *CHMP2B* mutation. **a** Sparse ubiquitin-immunoreactive NCIs (*arrows*) in the granule neurons of the dentate fascia. The NCIs are not labeled with anti-*TDP-43* antibodies (**b**). Ubiquitin-positive neuropil aggregates and a sparse NCI (*arrow*) in the frontal lobe of an affected 61-year-old female (**c**). *Scale bars a, b* 50 μ m, *c* 10 μ m

variably ubiquitin-positive, TDP-43-, α -internexin-, α -synuclein-, and tau-negative basophilic inclusions, the most likely neuropathologic diagnosis is basophilic inclusion body disease (BIBD) [58]. If all of the antibodies listed




Fig. 13 Basophilic inclusion body disease. **a** A basophilic inclusion (BI) in the precentral gyrus (motor cortex), with a similar, weakly ubiquitin-immunoreactive inclusion in (**b**). **c** Neurons with basophilic inclusions showing fine granular perikaryal *TDP-43* positivity in neurons with BIs on the left and negative in neurons with BIs on the right. **a** Hematoxylin and eosin; **b** ubiquitin, and **c** *TDP-43* immunohistochemistry. *Scale bars* 20 μ m

above and routine histological stains such as hematoxylin and eosin fail to reveal signature lesions, and if prion disease has been excluded by IHC or molecular genetics, the remaining FTLD diagnosis is dementia lacking distinctive histologic features (DLDH) [42]. However, it should be borne in mind that in many of the earlier histopathologic surveys, a relatively high proportion of cases of DLDH were encountered [32, 67]. Re-evaluation of such cases using either more sensitive ubiquitin IHC methodologies




Fig. 14 Neuronal intermediate filament inclusion disease. **a** Eosinophilic Lewy body-like NCI in a pyramidal neuron of the CA1 subfield of the hippocampus. **b** α -Internexin immunoreactive NCIs in layer III of the superior temporal gyrus. **c** Numerous α -internexin immunoreactive NCIs in the granule neurons of the dentate fascia. **a** Hematoxylin and eosin; **b, c** α -internexin immunohistochemistry. Scale bars 10 μ m

[25, 45, 51] or TDP-43 IHC [21] shows DLDH to be an uncommon cause of FTLN and, indeed, it still remains to be proven as a discrete entity with diagnostic criteria other than default characteristics being employed when all IHC and other methods have failed to reveal signature lesions.

Conclusions

The proposed criteria for the neuropathologic diagnosis of FTLN described here are an evolution of the previous criteria described by McKhann et al. [53]. When formulating these proposed criteria, we acknowledged revised staging

schemes for other disorders (e.g., AD and DLB), which recommend the use of IHC for the diagnosis of neurodegenerative diseases, replacing silver impregnation methods and averting the lack of reproducibility between centers when these stains are used. We have incorporated the recent identification of new entities into the nosology of FTLN. Most significantly, the discovery of TDP-43 as the major pathologic protein of most forms of FTLN identifies a novel molecular pathology, TDP-43 proteinopathy, and this is now included in the revised criteria. We have also considered the great progress in determining the molecular genetics of FTLN. In addition to FTLN with *MAPT* mutation, other familial subtypes are now recognized on the basis of the neuropathology of ubiquitin and/or TDP-43 IHC, biochemistry, and molecular genetics (FTLN with *PGRN*, *CHMP2B*, and *VCP* mutations, and cases linked to chromosome 9p), which reveal a strong correlation between genotype and neuropathologic phenotype. To facilitate neuropathologic diagnoses of FTLN at research and other centers, commercially available antibodies are now readily available for the identification of the underlying molecular pathologies (e.g., TDP-43 proteinopathy and tauopathy) and the rational diagnosis and nosology of a case of FTLN that comes to autopsy. The neuropathologic diagnostic algorithm described here is based on the current level of knowledge, but the consortium members appreciate that further study of TDP-43 proteinopathy may reveal new subtypes and that other FTLN entities may yet be identified. The proposed neuropathologic algorithm will facilitate efforts to improve the diagnosis of FTLN and encourage multi-center clinico-pathologic studies. Together, these efforts should improve the early and reliable neuropathologic diagnosis of the FTLN, raise the awareness of possible coexisting pathologies, and facilitate research efforts into pathogenesis and potential treatments where none currently exists.

Acknowledgments We thank the clinical, genetic, pathology, and technical staff of the collaborating centers for making information and tissue samples available for this study and we thank the families of patients whose generosity made this research possible. Support for this work was provided by grants from the National Institute on Aging of the National Institutes of Health (P50-AG05681, P01-AG03991, U01-AG16976, P30-AG13854, P30-NS057105, AG10124 and AG17586), the Buchanan Fund, the Winspear Family Center for Research on the Neuropathology of Alzheimer Disease, and the Charles and Joanne Knight Alzheimer Research Initiative.

References

- Alafuzoff I, Pikkarainen M, Al Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Bugiani O, Ferrer I, Gelpi E, Giaccone G, Graeber MB, Hauw JJ, Kamphorst W, King A, Kopp N, Korkolopoulou P, Kovacs GG, Meyronet D, Parchi P, Patsouris E, Preusser M, Ravid R, Roggendorf W, Seilhean D, Streichenberger N,

- Thal DR, Kretschmar H (2006) Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. *J Neuropathol Exp Neurol* 65:740–757
2. Amador-Ortiz C, Lin W-L, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. *Ann Neurol* 61:435–445
 3. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem Biophys Res Commun* 351:602–611
 4. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 442:916–919
 5. Behrens MI, Mukherjee O, Tu PH, Liscic RM, Grinberg LT, Carter D, Paulsmeier K, Taylor-Reinwald L, Gitcho M, Norton JB, Chakraborty S, Goate AM, Morris JC, Cairns NJ (2007) Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. *Alzheimer Dis Assoc Disord* 21:1–7
 6. Bigio EH, Lipton AM, Yen SH, Hutton ML, Baker M, Nacharaju P, White CL III, Davies P, Lin W, Dickson DW (2001) Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. *J Neuropathol Exp Neurol* 60:328–341
 7. Braak H, Braak E (1989) Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. *Neuropathol Appl Neurobiol* 15:13–26
 8. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 82:239–259
 9. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. *Cell Tissue Res* 318:121–134
 10. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol* 112:389–404
 11. Broe M, Hodges JR, Schofield E, Shepherd CE, Kril JJ, Halliday GM (2003) Staging disease severity in pathologically confirmed cases of frontotemporal dementia. *Neurology* 60:1005–1011
 12. Brun A, Englund B, Gustafson L, Passant U, Mann DMA, Neary D, Snowden JS (1994) Clinical and neuropathological criteria for frontotemporal dementia. *J Neurol Neurosurg Psychiatry* 57:416–418
 13. Buee L, Delacourte A (1999) Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. *Brain Pathol* 9:681–693
 14. Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH, Duyckaerts C, Stankoff B, Pillon B, Skullerud K, Cruz-Sanchez FF, Bigio EH, Mackenzie IR, Gearing M, Juncos JL, Glass JD, Yokoo H, Nakazato Y, Mosaheb S, Thorpe JR, Uryu K, Lee VM, Trojanowski JQ (2004) Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. *Neurology* 63:1376–1384
 15. Cairns NJ, Lee VM, Trojanowski JQ (2004) The cytoskeleton in neurodegenerative diseases. *J Pathol* 204:438–449
 16. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL III, Schneider JA, Kretschmar H, Carter D, Taylor-Reinwald L, Paulsmeier K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A, Xu Y, Forman MS, Lee VMY, Trojanowski JQ, Mackenzie IR (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. *Am J Pathol* (in press). doi:10.2353/ajpath.2007.070182
 17. Ciechanover A, Brundin P (2003) The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. *Neuron* 40:427–446
 18. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease (1997) *Neurobiol Aging* 18:S1–S2
 19. Cooper PN, Jackson M, Lennox G, Lowe J, Mann DM (1995) Tau, ubiquitin, and alpha B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia. *Arch Neurol* 52:1011–1015
 20. Cruts M, Gijselincx I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* 442:920–924
 21. Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du PD, Neary D, Snowden JS, Mann DM (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. *Acta Neuropathol* 113:521–533
 22. de Silva R, Lashley T, Strand C, Shiarli AM, Shi J, Tian J, Bailey KL, Davies P, Bigio EH, Arima K, Iseki E, Murayama S, Kretschmar H, Neumann M, Lippa C, Halliday G, Mackenzie J, Ravid R, Dickson D, Wszolek Z, Iwatsubo T, Pickering-Brown SM, Holton J, Lees A, Revesz T, Mann DM (2006) An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. *Acta Neuropathol* 111:329–340
 23. Dickson DW, Wertkin A, Kress Y, Ksiezak-Reding H, Yen SH (1990) Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects. *Lab Invest* 63:87–99
 24. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I (2002) Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. *J Neuropathol Exp Neurol* 61:935–946
 25. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, Chatterjee A, Hurtig HI, Karlawish JH, Rosen HJ, Van Deerlin V, Lee VM, Miller BL, Trojanowski JQ, Grossman M (2006) Frontotemporal dementia: clinicopathological correlations. *Ann Neurol* 59:952–962
 26. Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, Jhaveri BS, Karlawish JH, Pestronk A, Smith TW, Tu PH, Watts GD, Markesbery WR, Smith CD, Kimonis VE (2006) Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. *J Neuropathol Exp Neurol* 65:571–581
 27. Gibb WR, Luthert PJ, Marsden CD (1989) Corticobasal degeneration. *Brain* 112:1171–1192
 28. Goedert M, Spillantini MG, Cairns NJ, Crowther RA (1992) Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. *Neuron* 8:159–168
 29. Graham A, Davies R, Xuereb J, Halliday G, Kril J, Creasey H, Graham K, Hodges J (2005) Pathologically proven frontotemporal dementia presenting with severe amnesia. *Brain* 128:597–605
 30. Guyant-Marechal L, Laquerriere A, Duyckaerts C, Dumanchin C, Bou J, Dugny F, Le Ber I, Frebourg T, Hannequin D, Campion D (2006) Valosin-containing protein gene mutations: clinical and neuropathologic features. *Neurology* 67:644–651

31. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology* 44:2015–2019
32. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, Kril JJ, Halliday GM (2004) Clinicopathological correlates in frontotemporal dementia. *Ann Neurol* 56:399–406
33. Ironside JW, Head MW, Bell JE, McCauley L, Will RG (2000) Laboratory diagnosis of variant Creutzfeldt–Jakob disease. *Histopathology* 37:1–9
34. Iseki E, Yamamoto R, Murayama N, Minegishi M, Togo T, Katsuse O, Kosaka K, Akiyama H, Tsuchiya K, de Silva R, Lees A, Arai H (2006) Immunohistochemical investigation of neurofibrillary tangles and their tau isoforms in brains of limbic neurofibrillary tangle dementia. *Neurosci Lett* 405:29–33
35. Jellinger KA, Bancher C (1998) Senile dementia with tangles (tangle predominant form of senile dementia). *Brain Pathol* 8:367–376
36. Josephs KA, Holton JL, Rossor MN, Godbolt AK, Ozawa T, Strand K, Khan N, Al Sarraj S, Revesz T (2004) Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. *Neuropathol Appl Neurobiol* 30:369–373
37. Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS, Petersen RC, Davies P, Duara R, Graff-Radford NR, Uitti RJ, Rademakers R, Adamson J, Baker M, Hutton ML, Dickson DW (2007) Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. *J Neuropathol Exp Neurol* 66:142–151
38. Katsuse O, Dickson DW (2005) Ubiquitin immunohistochemistry of frontotemporal lobar degeneration differentiates cases with and without motor neuron disease. *Alzheimer Dis Assoc Disord* 19(Suppl 1):S37–S43
39. Kersaitis C, Halliday GM, Kril JJ (2004) Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. *Acta Neuropathol* 108:515–523
40. Kertesz A, Davidson W, McCabe P, Takagi K, Munoz D (2003) Primary progressive aphasia: diagnosis, varieties, evolution. *J Int Neuropsychol Soc* 9:710–719
41. Kipps CM, Davies RR, Mitchell J, Kril JJ, Halliday GM, Hodges JR (2007) Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. *Dement Geriatr Cogn Disord* 23:334–342
42. Knopman DS, Mastro AR, Frey WH, Sung JH, Rustan T (1990) Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. *Neurology* 40:251–256
43. Knopman DS, Boeve BF, Petersen RC (2003) Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. *Mayo Clin Proc* 78:1290–1308
44. Lantos PL, Cairns NJ, Khan MN, King A, Revesz T, Janssen JC, Morris H, Rossor MN (2002) Neuropathologic variation in frontotemporal dementia due to the intronic tau 10(+16) mutation. *Neurology* 58:1169–1175
45. Lipton AM, White CL III, Bigio EH (2004) Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. *Acta Neuropathol* 108:379–385
46. Liscic RM, Storandt M, Cairns NJ, Morris JC (2007) Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. *Arch Neurol* 64:535–540
47. Lowe J (1998) Establishing a pathological diagnosis in degenerative dementias. *Brain Pathol* 8:403–406
48. Lowe J, Hand N, Mayer RJ (2005) Application of ubiquitin immunohistochemistry to the diagnosis of disease. *Methods Enzymol* 399:86–119
49. Mackenzie IR, Baborie A, Pickering-Brown S, Plessis DD, Jaros E, Perry RH, Neary D, Snowden JS, Mann DM (2006) Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. *Acta Neuropathol* 112:539–549
50. Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E, Gass J, Cannon A, Rademakers R, Hutton M, Feldman HH (2006) The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. *Brain* 129:3081–3090
51. Mackenzie IR, Shi J, Shaw CL, Duplessis D, Neary D, Snowden JS, Mann DM (2006) Dementia lacking distinctive histology (DLDH) revisited. *Acta Neuropathol* 112:551–559
52. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Lodos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology* 65:1863–1872
53. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. *Arch Neurol* 58:1803–1809
54. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 41:479–486
55. Momeni P, Schymick J, Jain S, Cookson MR, Cairns NJ, Greggio E, Greenway MJ, Berger S, Pickering-Brown S, Chio A, Fung HC, Holtzman DM, Huey ED, Wassermann EM, Adamson J, Hutton ML, Rogava E, George-Hyslop P, Rothstein JD, Hardiman O, Grafman J, Singleton A, Hardy J, Traynor BJ (2006) Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. *BMC Neurol*. doi:10.1186/1471-2377-6-44
56. Morita M, Al Chalabi A, Andersen PM, Hosler B, Sapp P, Englund E, Mitchell JE, Habgood JJ, de Belleroche J, Xi J, Jongjaroenprasert W, Horvitz HR, Gunnarsson LG, Brown RH Jr (2006) A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. *Neurology* 66:839–844
57. Mukherjee O, Pastor P, Cairns NJ, Chakraverty S, Kauwe JS, Shears S, Behrens MI, Budde J, Hinrichs AL, Norton J, Levitch D, Taylor-Reinwald L, Gitcho M, Tu PH, Tenenholz GL, Liscic RM, Armendariz J, Morris JC, Goate AM (2006) HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. *Ann Neurol* 60:314–322
58. Munoz DG (1998) The pathology of pick complex. In: Munoz DG (ed) Pick's disease and pick complex. Wiley-Liss, New York, pp 211–241
59. Neary D, Snowden JS, Mann DM, Northen B, Goulding PJ, Macdermott N (1990) Frontal lobe dementia and motor neuron disease. *J Neurol Neurosurg Psychiatry* 53:23–32
60. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 51:1546–1554
61. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 314:130–133

62. Neumann M, Kwong LK, Truax AC, Vanmassenhove B, Kretschmar HA, Van Deerlin VM, Clark CM, Grossman M, Miller BL, Trojanowski JQ, Lee VM (2007) TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. *J Neuropathol Exp Neurol* 66:177–183
63. Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretschmar HA, Kimonis VE, Forman MS (2007) TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. *J Neuropathol Exp Neurol* 66:152–157
64. Okamoto K, Hirai S, Yamazaki T, Sun XY, Nakazato Y (1991) New ubiquitin-positive intraneuronal inclusions in the extra-motor cortices in patients with amyotrophic lateral sclerosis. *Neurosci Lett* 129:233–236
65. Rossor MN, Revesz T, Lantos PL, Warrington EK (2000) Semantic dementia with ubiquitin-positive tau-negative inclusion bodies. *Brain* 123:267–276
66. Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, Bruce J, Grossman M, Trojanowski JQ, Lee VM (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. *Am J Pathol* 169:1343–1352
67. Shi J, Shaw CL, Du PD, Richardson AM, Bailey KL, Julien C, Stopford C, Thompson J, Varma A, Craufurd D, Tian J, Pickering-Brown S, Neary D, Snowden JS, Mann DM (2005) Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. *Acta Neuropathol* 110:501–512
68. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Thusgaard T, Brandner S, Brun A, Rossor MN, Gade A, Johannsen P, Sorensen SA, Gydesen S, Fisher EM, Collinge J (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. *Nat Genet* 37:806–808
69. Snowden JS, Neary D, Mann DM (2002) Frontotemporal dementia. *Br J Psychiatry* 180:140–143
70. Spillantini MG, van Swieten JC, Goedert M (2000) Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). *Neurogenetics* 2:193–205
71. Srinivasan R, Davidson Y, Gibbons L, Payton A, Richardson AM, Varma A, Julien C, Stopford C, Thompson J, Horan MA, Pendleton N, Pickering-Brown SM, Neary D, Snowden JS, Mann DM (2006) The apolipoprotein E epsilon 4 allele selectively increases the risk of frontotemporal lobar degeneration in males. *J Neurol Neurosurg Psychiatry* 77:154–158
72. Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudo-bulbar palsy, nuchal dystonia and dementia. *Arch Neurol* 10:333–359
73. Taniguchi S, McDonagh AM, Pickering-Brown SM, Umeda Y, Iwatsubo T, Hasegawa M, Mann DM (2004) The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. *Neuropathol Appl Neurobiol* 30:1–18
74. Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, de Silva R, Lees A, Dickson DW (2002) Argyrophilic grain disease is a sporadic 4-repeat tauopathy. *J Neuropathol Exp Neurol* 61:547–556
75. Vance C, Al Chalabi A, Ruddy D, Smith BN, Hu X, Sreedharan J, Siddique T, Schelhaas HJ, Kusters B, Troost D, Baas F, de Jong V, Shaw CE (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. *Brain* 129:868–876
76. van der Knaap MS, Naidu S, Kleinschmidt-Demasters BK, Kamphorst W, Weinstein HC (2000) Autosomal dominant diffuse leukoencephalopathy with neuroaxonal spheroids. *Neurology* 54:463–468
77. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat Genet* 36:377–381
78. Weintraub S, Rubin NP, Mesulam MM (1990) Primary progressive aphasia. Longitudinal course, neuropsychological profile, and language features. *Arch Neurol* 47:1329–1335
79. Wightman G, Anderson VER, Martin J, Swash M, Anderton BH, Neary D, Mann D, Luthert P, Leigh PN (1992) Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. *Neurosci Lett* 139:269–274
80. Zhukareva V, Mann D, Pickering-Brown S, Uryu K, Shuck T, Shah K, Grossman M, Miller BL, Hulette CM, Feinstein SC, Trojanowski JQ, Lee VM (2002) Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. *Ann Neurol* 51:730–739

Symposium: Brain imaging and neuropathology

Neuropathology of mild cognitive impairment

Yuko Saito¹ and Shigeo Murayama²

¹Department of Pathology, Tokyo Metropolitan Geriatric Hospital, and ²Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

We aim to investigate the pathological background of mild cognitive impairment (MCI). The most recent 545 cases from the Brain Bank for Aging Research (BBAR) were studied, with a mean age of 80.7 years and male : female ratio of 324 : 221. Cases with clinical dementia rating scale (CDR) 0.5 were retrieved as the best substitute of MCI. CDR was retrospectively determined from clinical charts. Pathological examinations followed the BBAR protocol (JNEN 2004). Post mortem assessment of CDR was possible for 486 cases, and was 0 in 201 cases, 0.5 in 57 cases and 1–3 in 228 cases. CDR 0.5 group was clinicopathologically classified into 33 cases with degenerative changes, nine cases with vascular changes, four cases with combined degenerative and vascular changes, two with hippocampal sclerosis, two with trauma, one with metabolic disease and six with unremarkable changes. The degenerative group was further subclassified into groups with pure and combined pathology. The former consisted of six cases each with Alzheimer change (AC), argyrophilic grain change (AGC) and neurofibrillary tangle predominant change (NFTC), three each with Lewy body disease change without parkinsonism (DLBC) or Parkinson's disease (PDMCI) and one case with progressive supranuclear palsy. The latter consisted of three cases with AC plus AGC, two with AGC plus NFTC and one each with AC plus DLBC, DLBC plus amyotrophic lateral sclerosis and AGC plus DLBC. The pathological backgrounds of patients of class CDR 0.5 were varied and not restricted to AC.

Key words: amyloid β , argyrophilic grains, α -synuclein, clinical dementia rating scale, tauopathy.

Correspondence: Yuko Saito, MD, PhD, Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, 25-2 Sakaecho, Itabashi-ku, Tokyo, Japan. Email: yukosa@tmig.or.jp

Received 26 November 2006; revised and accepted 26 December 2006.

© 2007 Japanese Society of Neuropathology

INTRODUCTION

The concept of mild cognitive impairment (MCI) was proposed for the selection of the most vulnerable populations regarding the progression to dementia and to aid in the development of efficient early interventions. However, the concept remains controversial because it lacks the insight into the pathological background, or it has been expanded to encompass more cases than the original definition.

The clinical dementia rating scale (CDR)¹ was originally proposed for use in the objective evaluation of cognitive function, and later refined extensively regarding methodological points, and has now been adapted reliably for retrospective analysis. CDR 0.5 was the original requirement for MCI, and is thought to be the best reliable substitute for MCI² in retrospective studies.

In this study, the most recent serial autopsy cases of the Brain Bank for Aging Research (BBAR) were employed. The cases roughly represent an aging cohort of the Tokyo suburban area and are quite distinct from cases from memory clinics, whose chief complaints are amnesia. The results obtained here indicate that the pathology associated with CDR 0.5 was variable in a general aged population.

MATERIALS AND METHODS

Tissue source

Five hundred and forty-five serial autopsy brains from the BBAR were employed for this study. They consisted of consecutive autopsy cases from a general geriatric hospital providing community care, including full-time emergent medical service. The patients' ages ranged from 48 to 104 years, with a mean age of 80.7 ± 8.8 years, and the male : female ratio was 324 : 221.

Clinical information

Intellectual activity of daily living (IADL) was evaluated at discharge by attending nurses. The Mini-Mental State

Examination (MMSE)³ and/or Hasegawa dementia scale^{4,5} were included in clinical charts and conducted by attending physicians at admission. Two board-certified neurologists read the entire clinical records and determined CDR independently.¹ If the information in the clinical chart was not sufficient to determine CDR, interviews with the patients' attending physicians or caregivers were added to determine CDR. The results were recorded in the BBAR data base.

Selection of CDR 0.5 cases

The CDR 0.5 cases were selected from the BBAR database. All cases were reviewed again and the description of any memory disturbance that interfered with clinical intervention was confirmed in the clinical charts. In order to eliminate possible influence from systemic disorders, those CDR 0.5 cases with serious medical conditions at evaluation of cognitive state were excluded from the study.

Neuropathology

All serial autopsy cases were examined with the BBAR protocol described below, irrespective of clinical diagnosis.^{6,7} At autopsy, after taking photos of the whole brain, the non-dominant hemisphere or the hemisphere spared from focal lesions was serially sectioned at 7-mm thickness. The cerebrum was cut on the coronal plane, the brain stem on the axial plane, and the cerebellum on the sagittal plane. Photos were taken of all slices. Small pieces of the anterior amygdala, posterior hippocampus, frontal, temporal and occipital poles, supramarginal gyrus and rostral midbrain were directly fixed in 4% paraformaldehyde for 48 h and prepared for immunohistochemical and ultrastructural studies. The remaining slices were quick frozen and stored at -80°C . The hemisphere kept for morphological examinations was fixed in 20% neutral buffered formalin for 7–13 days and cut into 7-mm thick sections, similar to the contralateral hemisphere. Serial coronal sections of the cerebrum, axial sections of the brain stem, and sagittal sections of the cerebellum, together with the photos of the serial sections of the contralateral hemisphere were carefully compared with CT, MRI, single photon emission computed tomography (SPECT) and positron emission tomography (PET) images whenever available and correlated with clinical findings, including CSF biomarkers.

Paraffin-embedded sections of representative areas of the brain were examined. The selected anatomical structures included those recommended by the Consortium to Establish a Registry for Alzheimer Disease (CERAD),⁸ the Consensus Guidelines for the Diagnosis of Dementia with Lewy Bodies (DLB),⁹ Braak and Braak recommendation,¹⁰ and Diagnostic Criteria of Progressive Supranuclear Palsy.¹¹ These included the frontal pole, temporal

pole, cingulate gyrus, second frontal gyrus, accumbence and septal nuclei, amygdala, basal nucleus of Meynert, second temporal gyrus, anterior hippocampus with entorhinal and transentorhinal cortex, basal ganglia and hypothalamus with mamillary body, subthalamic nucleus, posterior hippocampus, thalamus with red nucleus, motor cortex, parietal lobe with intraparietal sulcus, visual cortex, midbrain, upper and middle pons, medulla oblongata, cerebellar vermis, dentate nucleus, and multiple cervical, thoracic, and lumbar levels of the spinal cord.

Six-micrometer-thick sections were routinely stained with HE and Klüver-Barrera method. Selected sections were stained with the modified methenamine,¹² Gallyas-Braak¹³ and Bielschowsky silver staining for senile changes, with Congo red for amyloid β deposition, and with elastica Masson trichrome staining for vascular changes.

Immunohistochemistry

Six-micrometer-thick serial sections were immunohistochemically stained, using a Ventana 20NX autostainer (Ventana, Tucson, AZ, US), as previously described.^{6,7} The antibodies applied to all the cases were: antiphosphorylated α -synuclein (psyn) (psyn#64¹⁴); phosphorylated tau (ptau) (AT8, monoclonal, Innogenetic, Temse, Belgium); amyloid β (A β) 11–28 (12B2, monoclonal, IBL, Maebashi, Japan); and ubiquitin (polyclonal, DAKO, Glostrup, Denmark). Selected cases were also examined with antibodies to: non-phosphorylated α -synuclein (LB509, a gift from Dr Iwatsubo); phosphorylated α -synuclein (polyclonal, Pser 129); A β 1–42 (polyclonal, IBL); glial fibrillary acidic protein (GFAP) (polyclonal, DAKO, Glostrup, Denmark); HLA-DR (monoclonal, CD68, DAKO, Glostrup, Denmark); phosphorylated neurofilament (monoclonal SMI31, Sternberger Immunochemical, Baltimore, MO, US); and myelin basic proteins (polyclonal, DAKO, Glostrup, Denmark).

Semiquantitative evaluation of senile changes

Lewy body (LB) pathology was classified into six LB stages as previously described.^{6,15} NFT pathology was classified into Braak's seven stages, and senile plaque (SP) into his four stages.¹⁰ Amyloid angiopathy (AAs) were categorized into four stages as previously specified.⁷ Amyloid angiopathy was classified into four stages using our criteria.¹⁶

Neuropathological diagnostic criteria for dementing disorders

Our modification¹⁷ of the NIA-Regan criteria¹⁸ was used for the diagnosis of Alzheimer's disease (AD): NFT stage \geq IV and SP stage = C. Cases were classified into "Early AD" when SP stage was \geq B and NFT stage was \geq III,

excluding AD cases as defined above. The diagnosis of dementia with Lewy bodies (DLB) was based on the first consensus guideline of DLB.⁹ The diagnoses of "dementia with grains" (DG) and "neurofibrillary tangle-predominant form of dementia" (NFTD) were based on Jellinger's criteria.^{19,20} Namely, DG presented with AG as the only explainable cause for dementia and NFTD as an excessive amount of NFTs in the hippocampus and SP stage comparable to age-matched controls. From the study of demented cases presenting with pure pathology, we adopted AG Stage III as DG and NFT stage III or IV and SP stage \leq A as NFTD. The diagnosis of vascular dementia (VD) was based on the NINDS-AIREN criteria.²¹ In addition, cases with definite strategic infarcts, multiple infarcts mainly involving gray matter and progressive subcortical leukoencephalopathy "Binswanger type" were included in VD. The diagnosis of "hippocampal sclerosis" was given to cases with marked neuronal loss and variable grade of gliosis in the CA1 of hippocampus, without other explainable changes.

Neuropathological diagnosis for CDR 0.5

CDR 0.5 cases were classified following the neuropathological diagnostic criteria for dementia described above. AC included pathological changes of AD and early AD. AGC was specified as its stage \geq stage II.⁷ NFTC was diagnosed when the pathological changes fulfilled the above criteria for NFTD. DLBC was diagnosed when the cases fulfilled the above criteria for DLB. "Hippocampal sclerosis" followed the above morphological description of "hippocampal sclerosis".

ApoE genotyping

Genomic DNA was extracted from the kidneys which had been snap-frozen at autopsy and apoE genotyping was performed with PCR, as previously reported.²² The typing was successfully completed in 462 out of 545 cases.

RESULTS

Clinical profiles

Clinical dementia ratings were available in 486 cases (89%) as follows: CDR 0 = 201 cases, CDR 0.5 = 57 cases, CDR 1 = 96 cases, CDR 2 = 31 cases, and CDR 3 = 101 cases.

Neuropathological diagnosis of CDR 0.5 cases, in comparison with demented cases

The neuropathological diagnosis of cases with CDR 0.5 was as follows. Thirty-three cases (57%) presented with mainly neurodegenerative pathology, nine cases (15%) with mainly vascular pathology, four (7%) with combined




Fig. 1 Neuropathology of with clinical dementia rating scale (CDR) 0.5 and CDR \geq 1. (A) Neuropathology of CDR 0.5. Degenerative background (64%) was approximately three times more frequent than vascular background (22%), when those cases with combined degenerative and vascular pathology were counted twice to be included into both categories. Each number represents the number of cases. (B) Neuropathology of CDR \geq 1. Degenerative dementia (60%) was two-fold more frequent than vascular dementia (32%).

neurodegenerative and vascular etiologies, two (4%) with hippocampal sclerosis, two (4%) with cerebral contusion, one with metabolic encephalopathy, and six (11%) with neuropathologically unremarkable findings (Fig. 1A).

The neuropathological diagnosis of cases with dementia (CDR1–3) was as follows. One hundred and thirty cases (57%) showed neurodegenerative pathology: 64 cases (28%) vascular pathology; nine (4%) combined neurodegenerative and vascular pathology; six (3%) Creutzfeldt Jacob disease; seven (3%) metabolic encephalopathy; four (2%), cerebral contusion; and one neuropathologically unremarkable changes.

The neurodegenerative pathology of CDR 0.5 cases was further subclassified as follows: six cases (19%) of AC; six (18%) of AGC; six (18%) of NFTC; three of DLBC; three (9%) of Parkinson's disease; one (3%) of PSP; three (9%) of AC plus AGC; one of AC plus DLBC; two (6%) of AGC plus NFTC; one of DLBC plus ALS; and one (3%) of AGC plus DLBC (Fig. 2A). In summary, AC was found in 31%, AGC in 36%, NFTC in 25%, and DLBC in 18% of CDR 0.5 cases.

The neurodegenerative pathology of dementia (CDR1–3) was classified as follows: 44 cases (34%) of AD; 22 (17%) of DLB; 15 (12%) of DG; nine (7%) of AD plus DLB; nine (7%) of PSP; six (5%) of NFTD; four (3%) of ALS; four (3%) of DG plus NFTD; two (2%) of AD plus DG; one (1%) of Pick disease; one (1%) of Huntington disease; one of DLB plus PSP plus DG; one of DLB plus diffuse neurofibrillary tangles with calcification; one of corticobasal degeneration plus DG; and one of DG plus PSP (Fig. 2B). In total, AD was found in 45%, DLB was found in 26% and DG was found in 18% of the cases with dementia.




Fig. 2 Detailed degenerative pathology of with clinical dementia rating scale (CDR) 0.5 and CDR ≥ 1 . (A) Degenerative pathology in CDR 0.5 consisted of 36% argyrophilic grain change (AGC), 31% Alzheimer change (AC), 24% the neurofibrillary tangle predominant change (NFTC) and 9% dementia with Lewy body disease change (DLBC). Those cases with combined degenerative pathology, for example, AC + DLBC. (B) Degenerative pathology in CDR ≥ 1 consisted of 43% Alzheimer's disease (AD), 26% dementia with Lewy bodies (DLB), 12% dementia with grain (DG) and 11% neurofibrillary tangle predominant form of dementia (NFTD). The higher frequency of AD and DLB among CDR ≥ 1 , than that of AC and DLBC among CDR 0.5, could be best explained by faster speed of exacerbation in these two groups, in AGC and NFTC.

Table 1 Case profiles of CDR 0.5 with pure Alzheimer change

Age/ gender	Brain weight (g)	Stages of senile changes				ApoE genotyping
		NFT	SP	LB	AG	
82/F	1070	III	C	0	0	34
88/F	1030	III	C	0	0	34
88/M	1370	III	B	0	0	33
91/M	1155	III	C	0	0	34
94/F	1550	III	B	0	1	33
94/F	1080	III	B	0	2	33

SP, senile plaque; LB, Lewy body; AG, argyrophilic grain; NFT, SP: Braak stage.¹⁰ LB, AG: our stage.^{6,7}

Senile tauopathy

We define "senile tauopathy" as tauopathy independent from A β accumulation, which includes argyrophilic grain disease (AGD), neurofibrillary tangle predominant disease (NFTD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), diffuse neurofibrillary tangle disease with calcification (DNTC) and other unclassified tauopathy. PSP and CBD are classified into Parkinson's disease-related disorders, but in the aged cohort, their initial symptoms could be cognitive decline and these cases should instead be classified as senile tauopathy. Clinical characterization of AGD and NFTD is still underway, because they are often complicated with each other and also coexist with PSP or CBD.

© 2007 Japanese Society of Neuropathology

Table 2 Case profiles of CDR 0.5 with pure argyrophilic grain disease (AGD)

Age/ gender	Brain weight (g)	Stages of senile changes				ApoE genotyping
		NFT	SP	LB	AG	
78	1150	II	A	1	3	34
80	1180	I	B	1	3	33
86	1177	II	B	1	3	33
93	1185	I	B	0	2	33
93	1190	II	A	0.5	2	33
94	1451	II	A	1	3	ND

SP, senile plaque; LB, Lewy body; AG, argyrophilic grain; NFT, SP: Braak stage.¹⁰ LB, AG: our stage.^{6,7}

Table 3 Case profiles of CDR 0.5 with pure neurofibrillary tangle predominant change

Age/ gender	Brain weight (g)	Stages of senile changes				ApoE genotyping
		NFT	SP	LB	AG	
88/M	1130	III	A	0	0	33
89/F	1221	IV	0	0	0	34
91/M	1090	IV	0	1	1	33
93/F	1100	III	0	0	0	33
99/F	1200	III	A	0	0	33

SP, senile plaque; LB, Lewy body; AG, argyrophilic grain; NFT, SP: Braak stage.¹⁰ LB, AG: our stage.^{6,7}

Table 4 Case profiles of CDR 0.5 with pure "dementia with Lewy body" change

Age/ gender	Brain weight (g)	Stages of senile changes				ApoE genotyping
		NFT	SP	LB	AG	
82/F†	973	I	0	2 (3‡)	0	33
88/M	1235	I	A	2 (3‡)	1	33
90/F	981	II	A	2 (5‡)	0	33

SP, senile plaque; LB, Lewy body; AG, argyrophilic grain; NFT, SP: Braak stage.¹⁰ LB, AG: our stage.^{6,7}

†A history of delusion during her stay in the hospital. ‡Lewy body scores, defined by the first Consensus Guideline of Dementia with Lewy bodies.⁹

In this cohort, senile tauopathy was found among 57% of CDR0.5 cases and 33% of demented cases.

Case profiles of CDR 0.5 with single pathology

Alzheimer change in CDR 0.5

The case profiles are summarized in Table 1. The mean age was 89.5 years. All cases fulfilled the criteria of "early AD". The allelic frequency of apoE $\epsilon 4$ was 25%, which was higher than that in the total cases (10.1%).

Argyrophilic grain change in CDR 0.5

The case profiles are summarized in Table 2. The mean age was 87.3 years. Four of the six cases (67%) showed abundant AGs, fulfilling the criteria for dementia with grains.⁷